Newly FDA-approved DOR/ISL offers an INSTI-free, 2-drug HIV treatment option with durable suppression and favorable safety.
Amy Colson, MD, MPH
Advertisement
https://crihealth.org/people/amy-colson-md-mph/
Articles by Amy Colson, MD, MPH
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
2
5 Ongoing Clinical Trials in Myeloproliferative Neoplasms
3
Defunding Co-Payment Assistance Disrupted nAMD Care
4
Aficamten Outperforms Metoprolol Across All Phases of Exercise in Obstructive HCM
5